OPSY HOLDING AB
NNGM:OPSYH9.20
SEK
+0.55
(+6.36%)
ISIN
SE0025399199
Return %
Stock
S&P 500
1Y
15.00
14.20
3Y
-50.27
81.12
5Y
-79.84
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Arne Thor
- Full Time Employees
- 7
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Stockholm Sweden
- Website
- opsy.se
- Similar Companies
- Business
- Opsy Holding AB is a Sweden-based healthcare provider specializing in ophthalmological care and clinical eye health services. Headquartered in Stockholm, Sweden, and founded in 2021, the company owns and operates specialized eye clinics delivering outpatient ophthalmic care, specialized diagnostics, and surgical interventions. The company delivers its services through primary clinical practice areas catering to regional public healthcare authorities, private insurance policyholders, and self-paying patients across Sweden. Opsy Holding AB offers a comprehensive range of medical and surgical ophthalmic services, including cataract surgery with standard monofocal, toric, and multifocal intraocular lens (IOL) implantations; refractive lens exchange (RLE) and corneal laser surgery for vision correction; medical retina diagnostics and intravitreal anti-VEGF injection therapies for age-related macular degeneration (AMD), diabetic retinopathy, and retinal vascular diseases; comprehensive glaucoma care comprising optical coherence tomography (OCT) imaging, visual field testing, selective laser trabeculoplasty (SLT), and filtration surgeries; oculoplastic and eyelid procedures such as blepharoplasty, ptosis repair, and periocular lesion excisions; and specialized outpatient ophthalmology consultations, corneal topography, and pediatric eye evaluations. In recent developments, Opsy Holding AB has advanced its expansion strategy through the acquisition and integration of private ophthalmic practices, the procurement and renewal of regional healthcare service agreements with Swedish county councils to address specialized surgical backlogs, the execution of equity financing initiatives to fund investments in high-precision diagnostic and surgical technologies, and corporate governance reorganizations aimed at strengthening clinical oversight and supporting multi-clinic operational scalability.